Feed PRFX
PR

PainReform Ltd.

PRFX · NASDAQ

$0.96 -8.42% (-$0.09)
1M +0.99%
Market Cap $77.4K
P/E Ratio -
Div. Yield -
ROE 46.74%

Bulios Fair Price

$1.11

15.4% upside

Trenutna cena

$0.96

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PRFX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
70 /100
Cheap
P/S 4.56x
P/B 0.01x
P/E N/A
Growth
0 /100
Declining
Rev. growth 41.75%
Book val. growth 8.14%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 4,864.71%
Net margin 28,458.80%
FCF margin 23,276.50%
Quality
0 /100
Poor
ROIC 52.15%
ROE 46.74%
Asset turnover 0.00x
Debt
67 /100
Low
Debt/Equity 0.00x
Current ratio 1.78x
Int. coverage -498.70x
Stability
50 /100
Moderate
Beta 1.04x
EPS volatility 45.18%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PRFX
Online

O podjetju

PainReform Ltd. (PRFX) is a biotechnology company focused on developing innovative therapeutics for pain management. Their main product is a local anesthetic-based medication called PRF-110, which is intended for the treatment of acute and chronic pain conditions. PainReform Ltd. focuses on leveraging its patented technologies to enhance the efficacy and durability of medicinal preparations, providing patients with effective and safe pain treatment options. The company also focuses on developing new drug formulations and therapeutic applications to improve the quality of life for patients suffering from various painful conditions. Shares of PainReform Ltd. (PRFX) could be suitable for investors who are tracking innovations in pain management and seeking investment opportunities in the biotechnology sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Efraim Cohen-Arazi

Employees

7

Headquarters

Tel Aviv

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.